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Abstract
Aims: Adenosine administration is needed for the achievement of maximal hyperaemia fractional flow 
reserve (FFR) assessment. The objective was to test the accuracy of Pd/Pa ratio registered during sub-
maximal hyperaemia induced by non-ionic contrast medium (contrast FFR [cFFR]) in predicting FFR and 
comparing it to the performance of resting Pd/Pa in a collaborative registry of 926 patients enrolled in 
10 hospitals from four European countries (Italy, Spain, France and Portugal).
Methods and results: Resting Pd/Pa, cFFR and FFR were measured in 1,026 coronary stenoses function-
ally evaluated using commercially available pressure wires. cFFR was obtained after intracoronary injection 
of contrast medium, while FFR was measured after administration of adenosine. Resting Pd/Pa and cFFR 
were significantly higher than FFR (0.93±0.05 vs. 0.87±0.08 vs. 0.84±0.08, p<0.001). A strong correlation 
and a close agreement at Bland-Altman analysis between cFFR and FFR were observed (r=0.90, p<0.001 
and 95% CI of disagreement: from –0.042 to 0.11). ROC curve analysis showed an excellent accuracy 
(89%) of the cFFR cut-off of ≤0.85 in predicting an FFR value ≤0.80 (AUC 0.95 [95% CI: 0.94-0.96]), sig-
nificantly better than that observed using resting Pd/Pa (AUC: 0.90, 95% CI: 0.88-0.91; p<0.001). A cFFR/
FFR hybrid approach showed a significantly lower number of lesions requiring adenosine than a resting Pd/
Pa/FFR hybrid approach (22% vs. 44%, p<0.0001).
Conclusions: cFFR is accurate in predicting the functional significance of coronary stenosis. This could 
allow limiting the use of adenosine to obtain FFR to a minority of stenoses with considerable savings of 
time and costs.
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Accuracy of cFFR in predicting functional stenosis
Introduction
Fractional flow reserve (FFR) is the ratio of two flows that can 
be calculated from the ratio of two pressures, provided they are 
both measured during maximal hyperaemia1. Consequently, the 
achievement of hyperaemia is the crucial prerequisite to assess 
FFR correctly. For this purpose, intravenous (i.v.) administration 
of adenosine is still considered the gold standard2. However, for 
cost, time and practical reasons, the intracoronary (i.c.) route is fre-
quently preferred3. On the other hand, i.c. adenosine also has some 
potential drawbacks, including significant bradyarrhythmias which 
may require the interruption of FFR assessment4,5. Considering that 
administration of other vasodilator agents2,6 is further limited by 
their side effects, it is not surprising that adenosine-free pressure-
derived indices, such as the instantaneous wave-free ratio (iFR), 
have been proposed, with, however, conflicting results7,8.
Previous studies have shown that radiographic contrast medium, 
routinely used during coronary angiography, and also during FFR 
assessment to check the correct positioning of the pressure wire, 
leads to coronary hyperaemia9,10, but to a lesser extent than with 
adenosine6. Thus, we hypothesised that the Pd/Pa ratio measured 
using an intracoronary pressure-sensitive guidewire following 
injection of radiographic contrast medium is diagnostically use-
ful and would commonly rule out the need for adenosine. In fact, 
we recently demonstrated that contrast medium-induced Pd/Pa, 
also known as contrast FFR (cFFR), is very accurate in predicting 
FFR, and could represent a valid surrogate for FFR, potentially 
limiting the use of adenosine to doubtful cases11,12. These stud-
ies represented the background for the CONTRAST study, a large 
multicentre study comparing the ability of cFFR to predict FFR 
versus resting indices. CONTRAST showed that cFFR is superior 
to resting Pd/Pa and iFR for predicting FFR, while resting Pd/Pa 
and iFR provided equivalent diagnostic accuracy13.
We designed the Multi-center Evaluation of the Accuracy of 
the Contrast MEdium INduced Pd/Pa RaTiO in Predicting FFR 
(MEMENTO-FFR) Study in order to elucidate further the accu-
racy of cFFR in predicting FFR in a large real-world series of 
lesions requiring functional assessment for clinical purposes.
Methods
The Multi-center Evaluation of the Accuracy of the Contrast 
MEdium INduced Pd/Pa RaTiO in Predicting FFR (MEMENTO-
FFR) was an international, multicentre, non-randomised, collabo-
rative, retrospective pooled analysis of the accuracy of cFFR in 
predicting FFR in patients with coronary artery disease in whom 
physiological lesion assessment was clinically indicated. Data 
were obtained from different local registries in 10 centres of four 
European nations, comprising 380 lesions in Italy (Rome), 177 in 
Portugal (Amadora and Carnaxide), 141 in France (Paris) and 328 
in Spain (Madrid, Barcelona, Santander, Valladolid, San Sebastian, 
Alicante). Some of these data have been included in previous pub-
lications11,12 (Online Appendix).
From December 2011 to July 2015, 962 patients with 1,026 cor-
onary artery stenoses were enrolled.
The identification of the stenosis which required functional 
assessment was left to the operator’s discretion. Clinical exclu-
sion criteria were recent myocardial infarction, severe valvular 
heart disease, acute heart failure, or advanced renal failure such 
that an additional dose of up to 20 mL of contrast would pose, 
in the opinion of the operator, unwarranted risk. The study was 
approved by the local ethics committees and conformed to the 
Declaration of Helsinki. Informed consent was obtained after 
explanation of the protocol and potential risks. Diagnostic cor-
onary angiography was performed using the radial or femoral 
approach. The choice of non-ionic radiographic contrast medium 
and modality of intracoronary injection were left to local prac-
tice (Online Appendix).
PRESSURE MEASUREMENTS
A 0.014-inch pressure monitoring guidewire (Certus™ or 
Aeris™ PressureWire™; St. Jude Medical, St. Paul, MN, USA; 
PrimeWire™ or Verrata® wires; Volcano Corporation, Rancho 
Cordova, CA, USA) was calibrated and introduced into the guid-
ing catheter. The pressure transducer was advanced just outside 
the tip of the guiding catheter, and the pressure measured by the 
sensor was then equalised to that of the guiding catheter. The 
femoral or brachial vein was used for systemic administration of 
adenosine. An FFR value of ≤0.80 was considered the significant 
ischaemic threshold.
STUDY PROTOCOL
The study consisted of three sequential steps separated by at least 
30 seconds until the return of Pd/Pa ratio to baseline value:
1. Resting Pd/Pa assessment: an initial period of at least one min-
ute provided a stable assessment of resting physiology for cal-
culation of resting Pd/Pa.
2. cFFR assessment: a single injection of radiographic contrast 
medium was performed according to standard local practice 
(Online Appendix). cFFR was calculated as the lowest ratio of 
distal coronary pressure divided by aortic pressure obtained 
after injection of radiographic contrast medium, in the first 
10 seconds after injection. Reproducibility of cFFR was tested 
in a subgroup of lesions repeating the injection of contrast 
medium 30 seconds after the first one (Online Appendix). After 
acquisition of the valid cFFR value, a flushing of the guiding 
catheter with saline was performed in order to avoid pressure 
damping due to contrast medium viscosity, to restore resting 
conditions and then to assess FFR correctly.
3. FFR assessment: maximal hyperaemia was induced by i.c. or 
i.v. adenosine administration, according to local practice (Online 
Appendix). The valid FFR value was considered the lowest Pd/
Pa value during stable hyperaemia when i.v. adenosine was 
used and the lowest Pd/Pa value in the first 10 seconds after 
injection in case of i.c. adenosine.
Patient symptoms, development of complete AVB or any other 
complication, were carefully recorded. The clinical data of 
enrolled patients were collected in dedicated electronic databases 
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at the time of the interventional procedure and merged in a single 
central database when the MEMENTO-FFR study was conceived 
by the authors.
STATISTICAL ANALYSIS
Categorical variables were expressed as percentages and analysed 
by Fisher’s exact test. Continuous variables were expressed as 
mean±SD and/or median (interquartile range) and compared using 
the paired t-test or the non-parametric Wilcoxon test, as appro-
priate. The relationship between cFFR and FFR was quantified 
with a coefficient of determination. The accuracy of cFFR in pre-
dicting FFR was assessed by measuring the area under the curve 
(AUC) by receiver operating characteristic (ROC) curve analysis. 
Correlation and agreement by Bland-Altman analysis with FFR, 
calculation of the optimal cut-off at Youden index in predicting an 
FFR ≤0.80 and its accuracy using a McNemar test between met-
rics, sensitivity, specificity, positive predictive value (PPV), neg-
ative predictive value (NPV) were obtained. All these measures 
were obtained for resting Pd/Pa too. Comparison of ROC curves 
for resting Pd/Pa and cFFR was performed using the DeLong 
method. Reproducibility of cFFR was tested by coefficient of 
determination in a lesion subset (Online Appendix).
Finally, as in previous reports11,13,14, we maximised the diagnos-
tic accuracy by identifying two cut-offs for both resting Pd/Pa and 
cFFR below and above which use of adenosine could be avoided 
with at least 95% safety, limiting adenosine for FFR assessment to 
intermediate values (the so-called “hybrid approach”). We decided 
to identify the lower cut-off as the lowest value of cFFR or rest-
ing Pd/Pa with a 95% specificity for an FFR ≤0.80, while the 
upper cut-off was identified as the lowest value with a 95% sen-
sitivity for an FFR ≤0.80. Accuracy, PPV, NPV and number of 
lesions requiring adenosine for both resting Pd/Pa/FFR and cFFR/
FFR hybrid approaches were calculated and compared using a chi-
square test with Yates’ correction.
Results
PATIENT CHARACTERISTICS AND SAFETY OF THE 
PROCEDURE
Patient characteristics are summarised in Table 1. The majority of 
patients had stable coronary artery disease with intermediate coro-
nary stenosis. FFR was evaluated inducing hyperaemia using i.v. 
adenosine in most of the cases, while cFFR was obtained using 
iomeprol and an automatic injection in the majority of patients 
(Table 1, Online Appendix).
Table 1. Patient clinical characteristics at baseline.
Age in years, median [interquartile range] 68 [60-75]
Male sex, n (%) 702 (68%)
Diabetes, n (%) 322 (33%)
Hypertension, n (%) 788 (82%)
Active smoking, n (%) 387 (40%)
Dyslipidaemia, n (%) 619 (64%)
Family history of CAD, n (%) 400 (41%)
Medications ASA, n (%) 900 (93%)
Clopidogrel, n (%) 640 (66%)
Beta-blockers, n (%) 726 (75%)
RAS antagonist, n (%) 718 (75%)
Calcium channel blockers, n (%) 138 (14%)
Statins, n (%) 758 (79%)
Stable angina/silent ischaemia, n (%) 510 (53%)
Acute coronary syndrome, n (%) 328 (34%)
Atypical pain, n (%) 124 (13%)
Prior MI, n (%) 254 (26%)
Previous PCI, n (%) 435 (45%)
% stenosis by visual estimation, median 
[interquartile range] 54 [50-60]
ASA: acetylsalicylic acid; CAD: coronary artery disease; MI: myocardial 
infarction; PCI: percutaneous coronary intervention; RAS: renin-
angiotensin system
As expected, resting Pd/Pa and cFFR were not associated with 
any symptom, while administration of i.c. adenosine for assess-
ing FFR was associated with 57 cases of bradycardia or complete 
AVB not requiring atropine or pacing, four cases of atrial fibrilla-
tion (two cases spontaneously resolved in less than five minutes, 
one case needed electrical cardioversion and one case resolved by 
i.v. amiodarone), and two cases of ventricular fibrillation needing 
DC shock. On the other hand, while administration of i.v. adeno-
sine was associated with 37 cases of unpleasant symptoms (dys-
pnoea, chest pain and facial flushing), there were only two cases 
of significant bradycardia (Table 2).
cFFR VS. FFR
FFR values were significantly lower than Pd/Pa and cFFR val-
ues (Figure 1). Both resting Pd/Pa and cFFR were significantly 
correlated to FFR (r=0.79, r²=0.62; p<0.001 and r=0.90, r²=0.81; 
p<0.001, respectively) (Figure 2A, Figure 2B). However, cFFR 
showed a higher r-coefficient and a lower spread of data with a very 
strong agreement with FFR by Bland-Altman analysis (Figure 2C, 
Figure 2D).
Table 2. Safety of different approaches for functional assessment.
Resting Pd/Pa
(962 pts)
cFFR
(962 pts)
i.v. adenosine 
(567 pts)
i.c. adenosine 
(395 pts)
Symptoms (dyspnoea, chest pain and facial flushing) 0 0 37 (7%) 0
Bradycardia – AV block 0 0 2 (<1%) 57 (14%)
Atrial fibrillation 0 0 0 4 (1%)
Ventricular fibrillation 0 0 0 2 (<1%)
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Accuracy of cFFR in predicting functional stenosis
Using ROC curve analysis, cFFR strongly predicts FFR with an 
AUC of 0.95 (95% CI: 0.94-0.96), significantly better than rest-
ing Pd/Pa, AUC 0.90 (95% CI: 0.88-0.91) (p<0.001). Moreover, 
for cFFR, the single cut-off of ≤0.85 had the best combination 
of sensitivity (87%) and specificity (90%) by the Youden index 
with a PPV of 82% and an NPV of 93%. More importantly, with 
this cut-off cFFR had an accuracy of 89% in identifying a correct 
1.0
0.8
0.6
0.4
0.94 [0.90-0.97] 0.88 [0.82-0.93] 0.85 [0.78-0.90]
Resting Pd/Pa cFFR FFR
Figure 1. Median values (interquartile ranges) of resting Pd/Pa, 
contrast fractional flow reserve (cFFR) and fractional flow reserve 
(FFR).
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Figure 2. FFR comparisons. A) & B) Correlation between resting Pd/Pa or contrast fractional flow reserve (cFFR) and fractional flow reserve 
(FFR) values. C) & D) Bland-Altman plots for the agreement between resting Pd/Pa or contrast fractional flow reserve (cFFR) and fractional 
flow reserve (FFR).
FFR. The best cut-off for resting Pd/Pa was ≤0.93, which showed 
a similar sensitivity (87%) and an NPV (92%) but a lower speci-
ficity (76%) and PPV (65%) and, more importantly, a significantly 
lower accuracy (80%, p<0.0001) in identifying a correct FFR as 
compared to cFFR ≤0.85 (Figure 3).
While FFR was ≤0.80 in 349 cases (34%), resting Pd/Pa and 
cFFR were ≤0.80 in 25 (2.4%) and 192 cases (19%), respectively.
Regarding the hybrid approach, both a resting Pd/Pa/FFR 
and a cFFR/FFR hybrid approach showed an equivalent excel-
lent accuracy (96%) (Figure 4A, Figure 4B). However, a cFFR/
FFR hybrid approach resulted in a significantly lower number of 
lesions requiring adenosine (22% vs. 44%, p<0.0001).
Subgroup analysis showed lack of difference for the type or 
the amount of contrast medium used, for its modality of admin-
istration and for the country of origin (Online Appendix, Online 
Figure 1, Online Table 1, Online Table 2, Online Table 3).
Discussion
The results of the MEMENTO-FFR study confirm that cFFR, cal-
culated as Pd/Pa after the induction of submaximal hyperaemia 
using an i.c. injection of standard radiographic contrast medium, 
accurately predicts FFR, significantly better than resting Pd/Pa. 
This could allow limiting the use of adenosine to obtain FFR to 
a minority of doubtful cases.
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The crucial prerequisite to assess FFR correctly is the achieve-
ment of maximal hyperaemia and for this purpose, given its 
favourable risk/efficacy profile, i.v. adenosine is still the gold 
standard1,15 and i.c. administration a valuable alternative11. This 
was also confirmed in our study in which the occurrence of symp-
toms and of significant side effects was relatively low, despite 
being potentially disturbing. Nevertheless, FFR is still underused 
in clinical practice and some authors have suggested further sim-
plifying functional assessment by using resting gradient-derived 
measures7,16,17. In particular, Sen et al proposed the instantaneous 
wave-free ratio (iFR) as a novel adenosine-free index of stenosis 
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AUC: 0.95 (95% CI: 0.94-0.96), p<0.001
Cut-off (Youden index): ≤0.85
Sensitivity: 87% Specificity: 90%
PPV 82% NPV 93%
Accuracy: 89% p=0.03
AUC: 0.90 (95% CI: 0.88-0.91), p<0.001
Cut-off (Youden index): ≤0.93
Sensitivity: 87% Specificity: 76%
PPV 65% NPV 92%
Accuracy: 80% p<0.001
cFFR vs.
resting Pd/Pa: p<0.001
cFFR
resting Pd/Pa
Figure 3. Receiver operating characteristic curve calculated using 
the threshold cut-off for fractional flow reserve (FFR) of ≤0.80. 
Contrast fractional flow reserve (cFFR) strongly predicts FFR (area 
under the curve [AUC] 0.95), significantly better than resting Pd/Pa 
(AUC 0.90). A cut-off of 0.85 of cFFR, obtained using the Youden 
index, had the best combination of sensitivity (87%) and specificity 
(90%) and an 89% accuracy in predicting a positive FFR, 
significantly better than resting Pd/Pa at the cut-off of 0.93.
1.0
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0.4 0.6 0.8 1.00.90 0.95
Resting Pd/Pa
Accuracy 96%
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FF
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Figure 4. Hybrid revascularisation strategy with resting Pd/Pa or cFFR and fractional flow reserve. Both a resting Pd/Pa/FFR (A) and a 
cFFR/FFR (B) hybrid approach showed an equivalent excellent accuracy (96%). However, a cFFR/FFR-based hybrid approach showed a 
significantly lower number of lesions requiring adenosine (22% vs. 44%, p<0.0001).
severity7. The notion of iFR is based on the hypothesis that there 
is a diastolic “wave-free” period when microvascular resistance 
is already constant and minimal and consequently does not need 
a further vasodilation. However, this hypothesis was challenged 
by Berry et al who showed in the VERIFY study that assess-
ment of iFR during infusion of adenosine gave significantly lower 
values than iFR in resting conditions and a much higher accu-
racy in predicting FFR18. Moreover, the VERIFY, RESOLVE and 
CONTRAST studies showed that iFR is not significantly more 
accurate in predicting FFR than resting Pd/Pa7,8,18. Overall, these 
studies consistently showed that non-hyperaemic indices have an 
accuracy of around 80% in predicting FFR. This was also con-
firmed in our study in which resting Pd/Pa exhibited an 80% accu-
racy. This implies that, if we take FFR as the gold standard, which 
is obtained (by definition) during maximal hyperaemia, we must 
induce a certain degree of hyperaemia to reach an acceptable level 
of accuracy. However, the burning questions are how to induce 
a sufficient hyperaemia and what is the amount of hyperaemia that 
we can give up without losing accuracy significantly.
Much of our knowledge in coronary physiology stems from the 
original studies of K. Lance Gould. It is worth noting that he used 
contrast medium to induce hyperaemia and describe the pressure/
flow/resistance relations in the presence of coronary stenosis9. In 
the following years, the development of FFR gave interventional 
cardiologists a realistic and practical tool to assess the functional 
significance of coronary artery stenosis in clinical scenarios19. In 
the early days of the history of FFR, contrast medium was again 
proven to induce reactive hyperaemia, probably related to its osmo-
lality10, although significantly less than adenosine6. For this reason, 
contrast medium was abandoned and eliminated from the list of 
recommended vasodilators1. Nevertheless, in clinical practice it is 
likely that submaximal hyperaemia induced by contrast medium 
could be sufficient to evaluate the vast majority of stenoses with-
out losing accuracy significantly. This working hypothesis was 
tested in the RINASCI study11. Indeed, we demonstrated that Pd/Pa 
713
EuroIntervention 2
0
16
;1
2
:70
8
-715
Accuracy of cFFR in predicting functional stenosis
registered after the injection of a standard dose of contrast medium 
was very accurate in predicting FFR and that the use of this 
approach could reduce the use of adenosine to one case in five. In 
the beginning, we preferred to avoid the use of the term FFR, which 
needs by definition maximal hyperaemia, and we called this index 
contrast medium-induced Pd/Pa ratio (CMR); nevertheless, in the 
following studies the more direct term cFFR was preferred. Indeed, 
the results of the RINASCI study were confirmed by Baptista, 
Martin-Reyes (abstract P4537 and P6374 at ESC Congress 2014) 
and Spagnoli et al12-14 and collectively represented the background 
for the CONTRAST study15. CONTRAST was a large multicen-
tre study comparing ability in predicting FFR by cFFR vs. rest-
ing indices (resting Pd/Pa, iFR). The results documented that cFFR 
was superior to resting Pd/Pa and iFR in predicting FFR while iFR 
and resting Pd/Pa provided equivalent diagnostic accuracy. With 
the MEMENTO-FFR study, we intended to corroborate these data 
independently in the largest real-world population of patients to 
date, even larger than the CONTRAST study. Notably, our results 
clearly confirm that cFFR is a reliable surrogate for FFR that can 
simplify functional assessment of coronary stenosis in clinical 
practice. We observed an accuracy of 89% for the single cut-off 
of cFFR ≤0.85, very similar to that observed in the CONTRAST 
study. In practice, this means that, without the use of adenosine, the 
operator has in cFFR a simple and always available tool to evalu-
ate the functional significance of coronary stenosis that is accurate 
in nine cases out of ten, much better than that which we can obtain 
using resting Pd/Pa (and probably iFR)13. Nevertheless, when the 
operator does not intend to renounce the highest possible accuracy, 
but at the same time he wants to minimise the use of adenosine, 
a cFFR/FFR hybrid approach exhibits an accuracy of >95% while 
the need for FFR is limited to about one case in five. This is half 
the number of lesions that would have needed FFR using a hybrid 
approach based on iFR or Pd/Pa8,13. In simple terms, this means 
that cFFR should be the preferred approach in clinical practice, and 
the use of resting indices cannot be justified since diagnostic accu-
racy is lower and adenosine would be used more often.
We think that cFFR could help in promoting a physiology-
based approach to the treatment of intermediate coronary artery 
stenosis. Indeed, cFFR, despite the impossibility of performing 
a pullback evaluation for the shortness of the contrast medium-
induced hyperaemia, could allow a rapid assessment of all major 
coronary branches, especially in multivessel disease, limiting 
standard FFR with adenosine infusion to a minority of doubt-
ful lesions (according to the proposed algorithm in Figure 5). 
Moreover, cFFR-guided PCI could be easier in comparison to 
FFR-guided PCI, not requiring additional adenosine and using 
the same amount of contrast medium needed to visualise the cor-
onary tree during PCI. This could allow replicating the favour-
able results of the FAME 1 study using a quicker solution, similar 
to the evaluation using resting iFR in the ongoing SYNTAX II 
study20,21. On the other hand, we should be aware that, while FFR 
has a well-known prognostic effect22, similar data about cFFR are 
still lacking. Consequently, although this information is going to 
Perform cFFR
Positive cFFR
(≤0.83)
Negative cFFR
(≥0.89)
Defer PCI
Negative FFR
(≥0.80)
Perform PCI
Positive FFR
(≤0.80)
FFR with adenosine
Equivocal
cFFR (0.84-0.88)
Intermediate coronary artery stenosis
Figure 5. A simple algorithm to limit adenosine administration only 
to doubtful cases. We consider a cFFR value ≤0.83 significant 
(consequently we suggest performing PCI), a cFFR value ≥0.89 not 
significant (consequently we suggest deferring PCI) and inducing 
maximal hyperaemia using adenosine for FFR assessment when 
cFFR is between 0.84 and 0.88. After that, PCI would be performed 
when FFR is ≤0.80 and deferred when FFR is >0.80.
be collected, in the meantime operators have to be cautious in 
drawing conclusions about the midterm and long-term prognosis 
associated with cFFR values.
We acknowledge that MEMENTO-FFR has some limitations. 
First, this is a collaborative pooled analysis and consequently dif-
ferent local protocols were used in assessing FFR and, more impor-
tantly, cFFR. However, considering the lack of impact of different 
contrast media and the modality of administration, this potential 
weakness further strengthens the wide applicability of cFFR to 
clinical practice. Second, we did not record raw data and pres-
sure tracings in a dedicated database. This is due to the real-world 
nature of our study and made it impossible to calculate offline iFR 
in order to compare cFFR to iFR on a large sample. However, tak-
ing into account that the RESOLVE and CONTRAST studies8,13 
showed that iFR is not significantly more accurate than resting 
Pd/Pa in predicting FFR, we can reasonably infer that the inclu-
sion of iFR assessment would not have changed the results of the 
MEMENTO-FFR study significantly.
Impact on daily practice
cFFR is remarkably accurate in predicting the functional signifi-
cance of coronary stenosis with FFR as the gold standard. cFFR 
is also superior to resting Pd/Pa both using a single cut-off and 
using a hybrid approach. The use of cFFR may allow limiting 
the use of adenosine only to doubtful cases with meaningful 
savings in time and costs.
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Supplementary data
Online Appendix. Details of local practices
Centre by centre local practice for contrast medium injec-
tion, induction of hyperaemia and basal Pd/Pa, cFFR and FFR 
assessment.
 – Rome (Italy):
 ▪ Modality of injection of contrast medium: automatic injec-
tion (Medrad® Avanta™; Bayer HealthCare, Warrendale, PA, 
USA).
 ▪ Type and amount of contrast medium: 6 ml of iomeprol 
(Iomeron®; Bracco SpA, Milan, Italy).
 ▪ Pressure wires: Certus™ or Aeris™ PressureWire; St. Jude 
Medical, St. Paul, MN, USA; PrimeWire™ or Verrata® wires; 
Volcano Corporation, Rancho Cordova, CA, USA.
 ▪ Drug for hyperaemia: adenosine i.v. (140 mcg/kg/min) 69%, 
i.c. (600 mcg) 31%.
 – Madrid, Barcelona, Santander, Valladolid, San Sebastian, 
Alicante (Spain):
 ▪ Modality of injection of contrast medium: automatic injec-
tion (ACIST CVi®; ACIST Europe B.V., Maastricht, The 
Netherlands).
 ▪ Type and amount of contrast medium: 8 ml for left coro-
nary artery and 5 ml for right coronary artery of iomeprol 
(Iomeron®; Bracco SpA, Milan, Italy).
 ▪ Pressure wires: Aeris™ PressureWire; St. Jude Medical, 
St. Paul, MN, USA.
 ▪ Drug for hyperaemia: adenosine i.v. (140 mcg/kg/min) 63%, 
i.c. (360 mcg for left coronary artery, 90 mcg for right coro-
nary artery) 37%.
 – Amadora (Portugal):
 ▪ Modality of injection of contrast medium: manual injection.
 ▪ Type and amount of contrast medium: 10 ml for left coro-
nary artery and 5 ml for right coronary artery of iopromide 
(Ultravist®; Bayer, Leverkusen, Germany) (75%), iodix-
anol (Visipaque®; GE Healthcare, Chalfont St. Giles, United 
Kingdom) (25%).
 ▪ Pressure wires: Certus™ or Aeris™ PressureWire; St. Jude 
Medical, St. Paul, MN, USA.
 ▪ Drug for hyperaemia: adenosine i.v. (140 mcg/kg/min).
 – Lisbon-Carnaxide (Portugal):
 ▪ Modality of injection of contrast medium: manual injection 
60%, automatic injection (ACIST CVi; ACIST Europe B.V., 
Maastricht, The Netherlands) 40%.
 ▪ Type and amount of contrast medium: 10 ml for left coro-
nary artery and 6 ml for right coronary artery of iomeprol 
(Iomeron®; Bracco SpA, Milan, Italy) (60%) and iodixanol 
(Visipaque®; GE Healthcare, Chalfont St. Giles, United 
Kingdom) (40%).
 ▪ Pressure wires: Certus™ or Aeris™ PressureWire; St. Jude 
Medical, St. Paul, MN, USA; PrimeWire™ or Verrata® wires; 
Volcano Corporation, Rancho Cordova, CA, USA.
 ▪ Drug for hyperaemia: adenosine i.v. (140 mcg/kg/min).
 – Paris (France):
 ▪ Modality of injection of contrast medium: manual injection.
 ▪ Type and amount of contrast medium: 10 ml for left coronary 
artery and 5 ml for right coronary artery of iopromide (Ultravist®; 
Bayer, Leverkusen, Germany) (75%) and iodixanol (Visipaque®; 
GE Healthcare, Chalfont St. Giles, United Kingdom) (25%).
 ▪ Pressure wires: Aeris™ PressureWire; St. Jude Medical, 
St. Paul, MN, USA.
 ▪ Drug for hyperaemia: adenosine i.v. (140 mcg/kg/min).
Reproducibility of cFFR in 103 lesions (10% of the entire lesion 
population) showed a very good agreement (r=0.99, p<0.0001) 
and agreement by Bland-Altman analysis (bias –0.001±0.01, 95% 
limits of agreement from –0.02 to 0.02).
FFR values were mildly correlated to visual estimation of coro-
nary stenosis (Online Figure 1).
Some of these data have been included in previous publica-
tions11,12. More specifically, 104 out of 380 lesions from Rome 
were included in the RINASCI study11, 138 in 141 lesions from 
Paris were included in the paper of Spagnoli et al12. Some of the 
other lesions from the CANICA group and from Portugal were 
included in abstracts but never published as full papers (oral pres-
entations by Baptista et al and Martin-Reyes et al at the ESC 
Congress, 2014). Collectively more than 75% of the lesions were 
not published in full papers.
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Online Figure 1. Correlation between FFR values and lesion severity 
by visual estimation. N.B. equal values are superimposed in the 
present graph.
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Online Table 1. Subgroup analysis for different countries.
Resting Pd/Pa cFFR
Correlation coefficients Bland-Altman analysis ROC curve analysis Correlation coefficients Bland-Altman analysis ROC curve analysis
Italy r=0.74 (0.69-0.79)
r2=0.55
p<0.001
Bias 0.083±0.05
95% limits of agreement:
from –0.015 to 0.182
AUC: 0.91
(95% CI: 0.88-0.94), 
p<0.001
r=0.89 (0.87-0.91)
r2=0.8
p<0.001
Bias 0.028±0.033
95% limits of agreement:
from –0.036 to 0.093
AUC: 0.98
(95% CI: 0.96-0.99), 
p<0.001
Spain r=0.75 (0.70-0.79)
r2=0.56
p<0.001
Bias 0.098±0.059
95% limits of agreement:
from –0.017 to 0.212
AUC: 0.87
(95% CI: 0.83-0.91), 
p<0.001
r=0.87 (0.84-0.89)
r2=0.75
p<0.001
Bias 0.047±0.043
95% limits of agreement:
from –0.038 to 0.131
AUC: 0.93
(95% CI: 0.89-0.95), 
p<0.001
Portugal r=0.81 (0.75-0.86)
r2=0.65
p<0.001
Bias 0.1±0.049
95% limits of agreement:
from –0.003 to 0.196
AUC: 0.90
(95% CI: 0.84-0.94), 
p<0.001
r=0.92 (0.89-0.94)
r2=0.84
p<0.001
Bias 0.033±0.033
95% limits of agreement:
from –0.031 to 0.096
AUC: 0.956
(95% CI: 0.92-0.98), 
p<0.001
France r=0.86 (0.80-0.90)
r2=0.73
p<0.001
Bias 0.106±0.064
95% limits of agreement:
from –0.02 to 0.232
AUC: 0.93
(95% CI: 0.88-0.97), 
p<0.001
r=0.94 (0.92-0.96)
r2=0.89
p<0.001
Bias 0.017±0.038
95% limits of agreement:
from –0.057 to 0.092
AUC: 0.96
(95% CI: 0.91-0.98), 
p<0.001
Online Table 2. Criterion values and coordinates of the ROC curve 
for resting Pd/Pa.
Criterion Sensitivity 95% CI Specificity 95% CI
<0.46 0.00 0.0-1.1 100.00 99.4-100.0
≤0.46 0.30 0.008-1.7 100.00 99.4-100.0
≤0.65 0.61 0.07-2.2 100.00 99.4-100.0
≤0.68 0.91 0.2-2.6 100.00 99.4-100.0
≤0.7 1.22 0.3-3.1 100.00 99.4-100.0
≤0.72 1.82 0.7-3.9 100.00 99.4-100.0
≤0.77 2.74 1.3-5.1 100.00 99.4-100.0
≤0.78 3.34 1.7-5.9 100.00 99.4-100.0
≤0.79 4.56 2.6-7.4 100.00 99.4-100.0
≤0.8 6.69 4.2-9.9 100.00 99.4-100.0
≤0.81 8.51 5.7-12.1 100.00 99.4-100.0
≤0.82 9.73 6.7-13.5 100.00 99.4-100.0
≤0.83 13.07 9.6-17.2 100.00 99.4-100.0
≤0.84 18.54 14.5-23.2 99.70 98.9-100.0
≤0.85 21.88 17.5-26.7 99.55 98.7-99.9
≤0.86 27.05 22.3-32.2 99.55 98.7-99.9
≤0.87 31.00 26.0-36.3 99.40 98.5-99.8
≤0.88 41.03 35.7-46.6 98.80 97.6-99.5
≤0.89 49.24 43.7-54.8 97.14 95.6-98.3
≤0.9 63.22 57.8-68.4 93.52 91.4-95.3
≤0.91 71.12 65.9-76.0 89.31 86.7-91.6
≤0.92 80.55 75.9-84.7 81.78 78.6-84.6
≤0.93 87.84 83.8-91.2 75.45 72.0-78.7
≤0.94 93.01 89.7-95.5 62.80 59.0-66.5
≤0.95 95.44 92.6-97.4 53.46 49.6-57.3
≤0.96 97.87 95.7-99.1 40.51 36.8-44.4
≤0.97 98.78 96.9-99.7 30.27 26.8-33.9
≤0.98 99.39 97.8-99.9 19.43 16.5-22.6
≤0.99 99.39 97.8-99.9 11.14 8.9-13.8
≤1 100.00 98.9-100.0 0.00 0.0-0.6
Diagnostic performance of resting Pd/Pa and cFFR over a range.
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Online Table 3. Criterion values and coordinates of the ROC curve 
for cFFR.
Criterion Sensitivity 95% CI Specificity 95% CI
<0.41 0.00 0.0-1.1 100.00 99.5-100.0
≤0.41 0.60 0.07-2.1 100.00 99.5-100.0
≤0.55 0.89 0.2-2.6 100.00 99.5-100.0
≤0.6 1.49 0.5-3.4 100.00 99.5-100.0
≤0.61 1.79 0.7-3.8 100.00 99.5-100.0
≤0.62 2.38 1.0-4.6 100.00 99.5-100.0
≤0.63 2.68 1.2-5.0 100.00 99.5-100.0
≤0.65 2.98 1.4-5.4 100.00 99.5-100.0
≤0.66 3.27 1.6-5.8 100.00 99.5-100.0
≤0.67 4.17 2.3-6.9 100.00 99.5-100.0
≤0.68 5.36 3.2-8.3 100.00 99.5-100.0
≤0.69 5.95 3.7-9.0 100.00 99.5-100.0
≤0.7 8.33 5.6-11.8 100.00 99.5-100.0
≤0.71 9.23 6.4-12.8 100.00 99.5-100.0
≤0.72 10.71 7.6-14.5 100.00 99.5-100.0
≤0.73 12.50 9.2-16.5 100.00 99.5-100.0
≤0.74 13.39 9.9-17.5 100.00 99.5-100.0
≤0.75 18.45 14.4-23.0 100.00 99.5-100.0
≤0.76 22.92 18.5-27.8 100.00 99.5-100.0
≤0.77 29.76 24.9-35.0 99.85 99.2-100.0
≤0.78 38.39 33.2-43.8 99.85 99.2-100.0
≤0.79 47.32 41.9-52.8 99.85 99.2-100.0
≤0.8 54.17 48.7-59.6 99.85 99.2-100.0
≤0.81 59.82 54.4-65.1 98.96 97.9-99.6
≤0.82 69.05 63.8-74.0 96.89 95.3-98.1
≤0.83 75.89 71.0-80.4 95.70 93.9-97.1
≤0.84 81.85 77.3-85.8 92.89 90.7-94.7
≤0.85 86.90 82.8-90.3 90.07 87.6-92.2
≤0.86 90.77 87.2-93.6 85.19 82.3-87.8
≤0.87 93.15 89.9-95.6 78.67 75.4-81.7
≤0.88 95.54 92.7-97.5 71.70 68.1-75.1
≤0.89 96.43 93.8-98.1 64.15 60.4-67.8
≤0.9 98.21 96.2-99.3 55.70 51.9-59.5
≤0.91 98.81 97.0-99.7 47.11 43.3-51.0
≤0.92 99.40 97.9-99.9 39.11 35.4-42.9
≤0.93 100.00 98.9-100.0 32.15 28.6-35.8
≤0.94 100.00 98.9-100.0 22.37 19.3-25.7
≤0.95 100.00 98.9-100.0 15.41 12.8-18.4
≤0.96 100.00 98.9-100.0 10.37 8.2-12.9
≤0.97 100.00 98.9-100.0 5.93 4.3-8.0
≤0.98 100.00 98.9-100.0 3.11 1.9-4.7
≤0.99 100.00 98.9-100.0 1.33 0.6-2.5
≤1 100.00 98.9-100.0 0.00 0.0-0.5
Diagnostic performance of resting Pd/Pa and cFFR over a range.
